American Association for Cancer Research
Browse
ccr-23-3841_supplementary_video_s5_suppsv5.mp4 (15.04 kB)

Supplementary Video S5 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma

Download (15.04 kB)
media
posted on 2024-05-01, 07:21 authored by Marc Wehrli, Samantha Guinn, Filippo Birocchi, Adam Kuo, Yi Sun, Rebecca C. Larson, Antonio J. Almazan, Irene Scarfò, Amanda A. Bouffard, Stefanie R. Bailey, Praju Vikas Anekal, Paula Montero Llopis, Linda T. Nieman, Yuhui Song, Katherine H. Xu, Trisha R. Berger, Michael C. Kann, Mark B. Leick, Harrison Silva, Diego Salas-Benito, Tamina Kienka, Korneel Grauwet, Todd D. Armstrong, Rui Zhang, Qingfeng Zhu, Juan Fu, Andrea Schmidts, Felix Korell, Max Jan, Bryan D. Choi, Andrew S. Liss, Genevieve M. Boland, David T. Ting, Richard A. Burkhart, Russell W. Jenkins, Lei Zheng, Elizabeth M. Jaffee, Jacquelyn W. Zimmerman, Marcela V. Maus

Supplementary Video S5. Meso^CD19 CAR T cells on AsPC1 + CAF

Funding

Swiss National Science Foundation

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

American-Italian Cancer Foundation (AICF)

Italian Foundation for Cancer Research (AIRC)

National Institutes of Health (NIH)

Sociedad Española de Oncología Médica (SEOM)

CRIS Cancer Foundation (CRIS Foundation)

DKMS Foundation (DKMS)

Deutsche Forschungsgemeinschaft (DFG)

Hopper-Belmont Foundation (HBF)

History

ARTICLE ABSTRACT

Targeting solid tumors with chimeric antigen receptor (CAR) T cells remains challenging due to heterogenous target antigen expression, antigen escape, and the immunosuppressive tumor microenvironment (TME). Pancreatic cancer is characterized by a thick stroma generated by cancer-associated fibroblasts (CAF), which may contribute to the limited efficacy of mesothelin-directed CAR T cells in early-phase clinical trials. To provide a more favorable TME for CAR T cells to target pancreatic ductal adenocarcinoma (PDAC), we generated T cells with an antimesothelin CAR and a secreted T-cell–engaging molecule (TEAM) that targets CAF through fibroblast activation protein (FAP) and engages T cells through CD3 (termed mesoFAP CAR-TEAM cells). Using a suite of in vitro, in vivo, and ex vivo patient-derived models containing cancer cells and CAF, we examined the ability of mesoFAP CAR-TEAM cells to target PDAC cells and CAF within the TME. We developed and used patient-derived ex vivo models, including patient-derived organoids with patient-matched CAF and patient-derived organotypic tumor spheroids. We demonstrated specific and significant binding of the TEAM to its respective antigens (CD3 and FAP) when released from mesothelin-targeting CAR T cells, leading to T-cell activation and cytotoxicity of the target cell. MesoFAP CAR-TEAM cells were superior in eliminating PDAC and CAF compared with T cells engineered to target either antigen alone in our ex vivo patient-derived models and in mouse models of PDAC with primary or metastatic liver tumors. CAR-TEAM cells enable modification of tumor stroma, leading to increased elimination of PDAC tumors. This approach represents a promising treatment option for pancreatic cancer.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC